Antipsychotics and mortality in Parkinsonism
Marras C, Gruneir A, Wang X, Fischer H, Gill SS, Herrmann N, Anderson GM, Hyson C, Rochon PA. Am J Geriatr Psychiatry. 2012; 20(2):149-58.
Publications
Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable
Gruneir A, Marras C, Fischer H, Wang X, Gill S, Rochon PA, Anderson GM. Pharmacoepidemiol Drug Saf. 2011; 20(3):221-8. Epub 2010 Dec 1.
Antipsychotic use in older adults with Parkinson’s disease
Marras C, Kopp A, Qiu F, Lang AE, Sykora K, Shulman KI, Rochon PA. Mov Disord. 2007; 22(3):319-23.
Atypical antipsychotics and parkinsonism
Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH. Arch Intern Med. 2005; 165(16):1882-8.
Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults
Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA. J Am Geriatr Soc. 2005; 53(8):1374-9.
New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice
Shulman KI, Sykora K, Gill SS, Mamdani M, Anderson G, Marras C, Wodchis WP, Lee PE, Rochon P. Am J Geriatr Psychiatry. 2005; 13(4):299-304.
Atypical antipsychotic drugs and risk of ischaemic stroke: population-based retrospective cohort study
Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SL, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. BMJ. 2005; 330(7489):445. Epub 2005 Jan 24.
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group. Neurology. 2005; 64(1):87-93.